Drug intelligence / Profile preview

MT-2002

Development stage: Preclinical
Lead developer: Macrophage Therapeutics
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules

Overview

MT-2002 is a preclinical-stage small molecule therapeutic being developed by Macrophage Therapeutics for the treatment of non-alcoholic steatohepatitis (NASH). It is designed as a targeted steroid that specifically modulates M1 pro-inflammatory macrophages via the C-C chemokine receptor type 2 (CCR2) pathway. By targeting CCR2, MT-2002 aims to deliver a steroid payload directly to the site of inflammation, thereby reducing the systemic side effects typically associated with corticosteroid therapy while effectively suppressing the inflammatory response in the liver.

Targets

CCR2 (Chemokine (C-C motif) Receptor 2)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on MT-2002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT-2002.

Explore the full profile